Clinical trial · Observational
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
NCT01891708CI-TRIAL-00011217unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastasis | Brain Neoplasm | PROBABILISTIC | 0.70 |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab, standard chemotherapy and radiation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS
- timeFrame
- 6 months
Secondary outcomes (1)
- measure
- OS
- timeFrame
- 18 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * non squamous cell non small cell lung cancer * with measurable disease * ECOG 0-1 Exclusion Criteria: \- patients received surgery in recent 4 weeks
References
Publications (0)
Data not yet available
No reference posted for this study.